Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: gawdhelpus, 21 Jun 2024 21:21
Last post: gawdhelpus, 21 Jun 2024 21:21
From an endemic disease called verbal diarrhea - it now looks, judging from certain posters on this board, that it has spread to the printed word. Can anyone suggest a cure?
Started: diggit1gold, 21 Jun 2024 18:11
Last post: diggit1gold, 21 Jun 2024 18:11
Why would anyone sell under 14p or 15p even. They've raised a decent amount but just an understandable amount less than wished for from pi's due to crappy circumstances. Wait for less if you want to chance it but what the hell. 15p is good imo. Don't really care what anyone negative thinks. :o).
Started: EmeraldCarrots, 21 Jun 2024 17:09
Last post: EmeraldCarrots, 21 Jun 2024 18:00
Back from school TwoGood? You seem to post 1st thing, then nothing until the schools have closed. Hilarious. Could easily be the case as to post here you don't have to give proof of age. Everyone should note that.
SPAM ⚠️ ALERT!⛔️☢️☣️⬇️📴〽️🚫🏳📢📣🖲
Device (that can catch circulating tumour cells, 99% of them still alive, from blood for analysis) is key to generating 10's it not hundreds of millions of pounds. I see him as an excellent salesman. I mean he's sold millions of pounds of Angle Shares to you, me, and thousands of others! Many are understandably upset that they bought into the placing in 2022 @ 80p. The directors at that time thought the Parsortix machines would "fly off the shelves" and clearly, they did not. However, all in not lost. Far from it. 290 machines are out there and each time a tube of blood is processed a new cassette is needed @ what..... $200 a go? It's likely that to promote Parsortix some machines were sold for a minimum fee, with x amount of cassettes also for next to no cost. Once the cheap cassettes run out then, assuming they don't stop using it (which seems unlikely) a steady revenue flow should appear if it has not already. We should not forget 99% of the CTC's Parsortix catches are alive and so perfect for Analysis. Not only the DNA, but the proteins and RNA too. CtDna analysis of blood only offers the DNA for analysis. The proteins and RNA are simply not there. This is why the likes of Astrazeneca and Eisai have placed orders with Angle Plc and IMHO a lot, lot more will follow in time.
All IMHO.
'How on earth is he going to make £5m in 2H? '
This is the key question Fevertreeman. The perplexing thing is that this figure is 5x the H1 revenue and yet the management have expressed confidence in achieving it. This is either the mother of all wishful thinking OR the management are aware of something which will significantly increase revenue and in which they have very high confidence. I can't believe that the management would be stupid enough for it to the the former, so I'm going with it being the latter.
Agree. The biggest issue remains Nero Newland and his big mouth! The Board seems powerless to hold him to account for throwing out forecasts without provides the smallest scintilla of evidence to support them. He has categorically told the market he’s happy with £6.4m (based on on discussions they had with the company) as recently as the FY results the other day. And yet he’s given a 30pc range for pending 1H results. How on earth is he going to make £5m in 2H? The total lack of supporting evidence is so typical of him, which then leads to more ii’s bailing out when he spectacularly fails to deliver. The latter has been set ages ago and Nero’s arrogance astounds me and others
no, it can't be bad. annoying that people can still buy just below the offer price of 15p.
mr newland needs to do more deals with the likes of astrazeneca and eisai pronto!
2 with astra so far. i think there will be more with them for sure. ab****ely definately.
all imho.
Let's be honest today's news re OO was not good, and yet the SP has held... that can't be bad, can it?
Started: EmeraldCarrots, 21 Jun 2024 16:28
Last post: EmeraldCarrots, 21 Jun 2024 16:28
Thought 1st thing this morning it might take a tumble, then pull back later. Actual was small decline, then pull back to quits.
Onwards and upwards!
Started: diggit1gold, 21 Jun 2024 07:48
Last post: TwoGood2Die, 21 Jun 2024 13:31
What proposed income they don't have other than a couple of tiny pilot schemes worth a few hundred thousand at best!
TwoGood2Die......'Current cash burn 🔥 £2m a month! '
You're obviously not accountant......what about offsetting the proposed income?
You are aware the result were for the year ending Dec 31st 2023?
Refer to 9th November business update RNS that explains the cost cutting.
Current cash burn 🔥 £2m a month!
That's after cost cutting!
Fevertree, I thought the £20m a year cash burn was the level before all of the severe cost cutting exercises you criticised earlier in the year? 🤔
Started: EmeraldCarrots, 21 Jun 2024 09:06
Last post: tomhuk2000, 21 Jun 2024 09:34
It is tedious isn’t it MOAB.
Carrot
You really are a card carrying unreconstructed ramper of the highest order. One has to admire your almost comical persistence. A bit like the band playing on the sloping deck of the Titanic.
Not a single new fact in your latest ramp, all c&p.
All IHMO, as you put it.
1. "Completion of the fundraising, announced separately today, alongside delivery of market expectations is anticipated by the Company to secure cashflow breakeven on a monthly basis by the end of 2025."
2. "Installed base of over 290 Parsortix® instruments with 210,000 cumulative samples processed at year end". Regular income as a new cassette is needed each time a blood sample is processed.
3. New contracts with both Eisai and Astrazeneca in the cancer drug trials side that could lead to multi-million-pound revenue should any of these drugs prove successful.
All IMHO.
Started: EmeraldCarrots, 20 Jun 2024 09:50
Last post: EmeraldCarrots, 20 Jun 2024 17:18
I suspect today would have been a good day to buy.
We will see.
I think that the OO take up will be small, which should be seen as a rebuff to Newland's approach to leadership. Too many have been burnt by wild forecasts that are not anchored in reality. Do you seriously believe that at the half year stage with 1-1.3m in the bag he can seriously hit the £6m+ he predicted?
Of good news to go with it I'd say.
We will see.
Started: EmeraldCarrots, 19 Jun 2024 09:15
Last post: TwoGood2Die, 19 Jun 2024 14:27
🥕' you do know you have exceeded your daily 'spam' limit don't you?
Hello.
Started: Fevertreeman, 19 Jun 2024 09:40
Last post: Fevertreeman, 19 Jun 2024 09:40
Worth skimming through the Annual Report published today and now on website. Largely a cut n paste job form the results announcement tho' Griffiths's financial review provides more colour than I was expecting.
Started: EmeraldCarrots, 19 Jun 2024 09:25
Last post: EmeraldCarrots, 19 Jun 2024 09:37
............... ask now 15p, too late.
Ask getting 14.5p now. About to click up methinks.
Personally, I expect good news soon as it's been a while..............
Mr Newland said that the news Eisai Inc. (top 100 Japanese Co.) and Astrazeneca (7th largest Pharma Co. in the World) are now on the books had sparked loads of interest from other major Plc's carrying out cancer drug trials. To me it is inconceivable that the list of Cancer drug trial clients won't steadily increase. We will see.
All IMHO.
Started: EmeraldCarrots, 18 Jun 2024 21:31
Last post: EmeraldCarrots, 19 Jun 2024 08:51
Correction. Result of open offer due Friday, 21st June.
"Announcement of the result of the Open Offer 21 June"
Presumably the result of the open offer in an RNS, and maybe some other news.
Started: EmeraldCarrots, 18 Jun 2024 16:22
Last post: EmeraldCarrots, 18 Jun 2024 16:22
Hello.
Started: EmeraldCarrots, 18 Jun 2024 12:35
Last post: EmeraldCarrots, 18 Jun 2024 12:35
Below the offer price of 15p, just (ask 14.5p).
Started: EmeraldCarrots, 17 Jun 2024 11:44
Last post: TwoGood2Die, 17 Jun 2024 20:58
ANGLE plc
LON: AGL
OverviewFinancialsCompare
13.75 GBX -1.22 (-8.18%)past 5 days
17 Jun, 16:32 BST • Disclaimer
Why pay 15p when you can get it for 13p!
Complete lack of underlying confidence!
Have now placed orders with Angle. These are for Angle to use their patented Parsortix machine to catch circulating tumour cells from the blood stream of people who have cancer. Then for Angle to analyse them in ways that simply cannot be done using Ctdna analysis of the blood. Only the original tumour (before being cut out) and the circulating tumour cells have this information. Simple as that. Companies like Illumina and Thermo Fisher simply must know that analysing the circulating tumour cells can give very valuable information. Information that simply cannot be obtained by analysing blood CtDna (fragments of DNA in the blood) because it does not exist in these DNA fragments!
The big Pharma Co’s know this, and it is concerning more of the massive Pharma Co’s have not, as yet, placed orders with Angle Plc. Hopefully now Astrazeneca have placed a couple of orders things will really start to move.
All IMHO.
Started: EmeraldCarrots, 17 Jun 2024 15:08
Last post: EmeraldCarrots, 17 Jun 2024 15:08
Co is on the books. When that lands what's the betting the sp will go North of the 15p placing and open offer price? Dead cert I'd say.
All IMHO.
Started: Fevertreeman, 17 Jun 2024 10:16
Last post: smithfields, 17 Jun 2024 11:10
You'd have thought that the company would have given the open offer a bit of support?...apparently not.
If GRAIL the market leader for cancer blood test is also having lacklustre IPO expecting just market cap of $500mil in NASDAQ listing spin off from Illuminia.
What are the chances of Angle operating in the same field generating significant interest from shareholders.. need solid results to turn this around.. imo,dyor.
Not a surprise given share price couldn't hold 15p level, and the fact that retail s/holders remain very wary of Newland's relentless hype. Newland's confident assertion that "management remains confident in delivering strong growth in 2024 in line with current market expectations", looks suspect. A 30pc range for H1 revenues of £1m- £1.3m hardly adds to
the sense of confidence that Newland can deliver £5m+ in 2H to achieve consensus of £6.45m revenues. To do that he will need to have deals already in pipeline, or very much close to it, to close them out before Dec 31st. And we are entering the summer months when sod all happens.
£6.54m current year forecast is
Started: EmeraldCarrots, 14 Jun 2024 11:09
Last post: Moab, 17 Jun 2024 09:08
Do we really need paid content on this BB?. Is Sunday overtime?
Conclusion. Angle shares are on the verge of going 50p plus. Apart from anything else (and there is a lot of other things they are involved with), just their services arm are likely within 12 months to be generating millions of pounds. Likely to snowball from there to tens of millions of pounds. The Parsortix machine enables the capture (from a standard blood sample) of circulating tumour cells (cancerous cells in the blood stream that have come from the original tumour). With their Parsortix system 99% of the cells are alive, perfect for analysing not only the DNA. Also, the proteins and RNA too, which CANNOT BE DONE USING CtDna analysis of the blood. Therefore, Circulating Tumour Analysis offers information that simply is not available from CtDna, because that information is not there, as in missing from the DNA fragments.
The Services side has the following contracts to date.
1. Eisai Inc. "ANGLE's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible.". Note there are loads of cancer drug trials where they need to know the HER2 status of a patient throughout the treatment as it can change.
2. Astrazeneca. “ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response.
3. Astrazeneca. “agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.”.
IMHO this list will expand to 5, 8, 12, 18, 26, 35 etc…….
Waiting for the RNS’s………………..
All IMHO...
Conclusion. Angle shares are on the verge of going 50p plus. Apart from anything else (and there is a lot of other things they are involved with), just their services arm are likely within 12 months to be generating millions of pounds. Likely to snowball from there to tens of millions of pounds. The Parsortix machine enables the capture (from a standard blood sample) of circulating tumour cells (cancerous cells in the blood stream that have come from the original tumour). With their Parsortix system 99% of the cells are alive, perfect for analysing not only the DNA. Also, the proteins and RNA too, which CANNOT BE DONE USING CtDna analysis of the blood. Therefore, Circulating Tumour Analysis offers information that simply is not available from CtDna, because that information is not there, as in missing from the DNA fragments.
The Services side has the following contracts to date.
1. Eisai Inc. "ANGLE's Portrait HER2 assay provides a way to evaluate HER2 status in patients where a tissue biopsy at the metastatic site either fails or is not feasible.". Note there are loads of cancer drug trials where they need to know the HER2 status of a patient throughout the treatment as it can change.
2. Astrazeneca. “ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response.
3. Astrazeneca. “agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies.”.
IMHO this list will expand to 5, 8, 12, 18, 26, 35 etc…….
Waiting for the RNS’s………………..
All IMHO.
Started: EmeraldCarrots, 13 Jun 2024 10:02
Last post: TwoGood2Die, 15 Jun 2024 06:59
ANGLE plc
LON: AGL
OverviewFinancialsCompare
14.00 GBX -0.86 (-5.79%)past 5 days
14 Jun, 17:05 BST • Disclaimer
ANGLE plc
LON: AGL
OverviewFinancialsCompare
14.02 GBX -0.84 (-5.65%)past 5 days
14 Jun, 14:51 BST • Disclaimer
TGTD,
Day Trader = Holds a stock for minutes, hours, or maybe days. Unless they get trapped in which case they will chew their own arm off to get away (sell at a loss and move on). Usually on a swing trade basis or momentum. No real knowledge of the investment is essential.
An investor = Makes money from an investment. The period over which they hold is entirely optional, but taking profit is a high priority. It is highly likely that an investor understands the proposition extremely well and dips in and out of the investment capitalising on share price movement.
Long Term Holder = Prepared to hold over the long term even if that means they leave profits (regardless of size £££) on the table as they believe there is more value to be realised at a future point (usually undetermined) in time. This is very high risk as by not taking profits, errors judging future value or market conditions change can lead to severe losses.
Just my opinion and of course one should do their own research. In any case, I think it is unlikely EC is a day trader.
ATB
Bantham
He's a day trader not a long term investor..
Hence the constant daily 'copy and past' spamming posts of previous articles or RNS's releases from months ago ramping the share in a futile bid to sell out on the next spike..'rinse and repeat'..he got caught out recently posting here when he meant to post on another board..bragging about his day trade profiteering and spent most of the day here back peddling saying he wasnt day trading Angle stock lol!..😉😇
EC - as Angle’s greatest cheerleader you really should be buying shares in the placing to support the company rather than picking up shares at a penny off the placing price which has no benefit to the company.
Started: EmeraldCarrots, 14 Jun 2024 12:37
Last post: EmeraldCarrots, 14 Jun 2024 12:37
Look closely.
https://www.youtube.com/watch?v=5Bdw7iZr3ac
Started: TwoGood2Die, 12 Jun 2024 16:15
Last post: TwoGood2Die, 13 Jun 2024 09:52
ANGLE plc
LON: AGL
OverviewFinancialsCompare
13.90 GBX −0.60 (4.14%)today
13 Jun, 09:49 BST • Disclaimer
Disagree with you on this one TG2D. For the sake of a tiny percent higher buy price you can actually fund the company directly by taking up the retail offer.
If you are buying open market anyway, I personally think it’s better in the long run to pay slightly more to give the company more cash.
That’s my opinion anyway
At 14.38p simple not worth retail participating with the cash placement at 15p!
Started: TwoGood2Die, 12 Jun 2024 16:07
Last post: smithfields, 12 Jun 2024 19:32
Theranos...was built on 'smoke and mirrors'...
https://www.msn.com/en-gb/money/other/how-this-billionaire-lost-everything-and-ended-up-in-jail/ss-BB1nW750?ocid=hpmsn&cvid=07fcbf99ba6b40a493f1aae98e4405b5&ei=9#image=18
Thought I would beat EC to it for a change and spam the BB all day!
htTps://youtu.be/anwy2MPT5RE?si=oCEbmoeoITs3Pk_l
Started: Fevertreeman, 12 Jun 2024 16:03
Last post: TwoGood2Die, 12 Jun 2024 16:05
Fevertreeman
Makes perfect sense why support the cash placement paying 15p when you can buy now as it's cheaper assuming you expect no further price instability.
Given the share price is stuck below 15p and you can buy at around 14.8p, it tends to suggest that retail has finally wised up to Newland's abysmal record of hyping news, missing forecasts, and burning thru cash. I am not supporting the 15p offer because I topped up today.
Started: EmeraldCarrots, 12 Jun 2024 12:28
Last post: EmeraldCarrots, 12 Jun 2024 13:09
HtTps://en.wikipedia.org/wiki/Theranos
The attached highlights why health bodies in particular the FDA and big pharma are so cautious and rightly so..
EC
Probably because they don't have full confidence in the test results hence the pilot studies..A sensible commercial and legal approach given the huge risks, fines, penalties om the USA and not to say bad publicity if they go full guns blazing only to find there were material issues, a wrong diagnosis was made, wrong drugs or treatment decisions made, or loved ones and relatives told a patient did or didn't have cancer when the opposite was true. There is no margin or room for error here!
Patient care and correct diagnosis and treatment is paramount making a quick commercial buck out the service should always be secondary!
The big Pharma Co's with the big budgets should employ Companies like Angle who are at the cutting edge of liquid biopsy advances. The truth is it is early days as far as what can be gained by analysing circulating tumour cells. As they are the very cells that can spread a cancer it's obvious, they must contain valuable information to do with the cancer. Only by analysing the cancer cells before, during and after a cancer treatment will we find out what a drug has done (if anything) to slow or hopefully eliminate the cancer. The amazing thing to me is some cancer treatments sometimes work very well and sometimes they don't. As I understand it, they don't fully understand why. The contracts so far with Eisai and Astrazeneca will throw more light on what analysing the circulating tumour cells can tell us. Personally, I think it is a disgrace that more of the huge Pharma Co's have not yet employed Angle's expertise to find out what information the circulating tumour cells can give us during the trials. I suspect it is cost, and this is why in my opinion it is a disgrace. How on earth can these massive Pharma Co’s justify doing a cancer drug trial WITHOUT analysing the circulating tumour cells? Apart from anything else there is quite obviously a very good chance of the data being extremely useful. I mean, these are cancerous cells from the original tumour. If they have not got important information what on Earth does? The following RNS’s about the “CTC & ctDNA dual analysis” show one of the ways Angle can help.
https://www.lse.co.uk/rns/AGL/breakthrough-clinical-results-b0km788ah9aflqm.html
https://www.lse.co.uk/rns/AGL/parsortix-and-assays-being-showcased-at-eacr-2024-xhvpvzmogvybaro.html
All IMHO.
Started: diggit1gold, 12 Jun 2024 10:07
Last post: Moab, 12 Jun 2024 10:19
Diggit
That is a terribly sad story about a rare, and so far untreatable sarcoma. I lost a good friend from the same. My sincere sympathy.
Moab
Any improvement on early cancer detection rates from any Bio has to be greatly welcomed. Too late unfortunately for my only son Calvin (forever 29) who succumbed to late presentation large bone Sarcoma of the Pelvis and Iliac crest bone on 7/5/2023. Into hospital on the Thursday and passed away on the Sunday GRHS. It's actually a blessing in disguise that he was taken quickly. This Sunday just like on the corresponding day last year isn't going to be a bundle of laughs. 😢 :o( .